Mesoblast (NASDAQ: MESO) is one of 184 public companies in the “Biotechnology & Medical Research” industry, but how does it compare to its peers? We will compare Mesoblast to related companies based on the strength of its institutional ownership, valuation, dividends, risk, profitability, analyst recommendations and earnings.
This table compares Mesoblast and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Mesoblast has a beta of 2.68, meaning that its share price is 168% more volatile than the S&P 500. Comparatively, Mesoblast’s peers have a beta of 1.55, meaning that their average share price is 55% more volatile than the S&P 500.
Institutional & Insider Ownership
2.9% of Mesoblast shares are owned by institutional investors. Comparatively, 49.6% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 14.7% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Mesoblast and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Mesoblast||$2.41 million||-$76.81 million||-8.10|
|Mesoblast Competitors||$217.29 million||-$39.39 million||-80.32|
Mesoblast’s peers have higher revenue and earnings than Mesoblast. Mesoblast is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
This is a summary of recent ratings and target prices for Mesoblast and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Mesoblast currently has a consensus target price of $14.25, indicating a potential upside of 125.47%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 17.56%. Given Mesoblast’s stronger consensus rating and higher possible upside, equities analysts plainly believe Mesoblast is more favorable than its peers.
Mesoblast Company Profile
Mesoblast Limited is engaged in developing cell-based medicines. The Company has leveraged its technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high, unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.